In conclusion, we demonstrated that pre-existing ANA and a characteristic liver histology including CD8+ cells dominancy and granulomatous hepatitis could be biomarkers for the diagnosis of iCIs-related hepatitis in NSCLC with anti-PD-1 therapy. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.